Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
11
|
| pubmed:dateCreated |
1997-7-24
|
| pubmed:abstractText |
Engraftment kinetics after high-dose chemotherapy (HDC) were evaluated in patients receiving autologous peripheral blood stem cell (PBSC) infusions with a low CD34+ cell content. Forty-eight patients were infused with < 2.5 x 10(6) CD34+ cells/kg; 36 because of poor harvests and 12 because they electively received only a fraction of their harvested cells. A median of 2.12 x 10(6) CD34+ cells/kg (range, 1.17-2.48) were infused following one of seven different HDC regimens. All patients achieved absolute neutrophil counts > or = 0.5 x 10(9)/l at a median of day 11 (range, 9-16). Forty-seven patients achieved platelet counts > or = 20 x 10(9)/l at a median of day 14 (range, 8-250). Nine of 47 (19%) had platelet recovery after day 21, 4/47 (9%) after day 100 and one died on day 240 without platelet recovery. Twenty-six patients (54%) died of progressive disease in 51-762 days; 22 (46%) are alive at a median of 450 days (range, 94-1844), 17 (35%) of whom are surviving disease-free at a median of 494 days (range, 55-1263). No patient died as a direct consequence of low blood cell counts. These data demonstrate that PBSC products containing 1.17-2.48 x 10(6) CD34+ cells/kg resulted in relatively prompt neutrophil recovery in all patients but approximately 10% had delayed platelet recovery.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
0268-3369
|
| pubmed:author |
pubmed-author:AllenCC,
pubmed-author:BucknerC DCD,
pubmed-author:DrapkinRR,
pubmed-author:GrandRR,
pubmed-author:HazeltonBB,
pubmed-author:KaywinPP,
pubmed-author:LonginKK,
pubmed-author:PourSS,
pubmed-author:RedmondJJ,
pubmed-author:SchwartzbergL SLS,
pubmed-author:TauerKK,
pubmed-author:UngerPP,
pubmed-author:WeaverC HCH,
pubmed-author:ZhenBB
|
| pubmed:issnType |
Print
|
| pubmed:volume |
19
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1103-10
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:9193753-Antigens, CD34,
pubmed-meshheading:9193753-Female,
pubmed-meshheading:9193753-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:9193753-Humans,
pubmed-meshheading:9193753-Male,
pubmed-meshheading:9193753-Neoplasms,
pubmed-meshheading:9193753-Neutrophils,
pubmed-meshheading:9193753-Platelet Count,
pubmed-meshheading:9193753-Transplantation, Autologous,
pubmed-meshheading:9193753-Transplantation Conditioning
|
| pubmed:year |
1997
|
| pubmed:articleTitle |
Engraftment and outcomes of patients receiving myeloablative therapy followed by autologous peripheral blood stem cells with a low CD34+ cell content.
|
| pubmed:affiliation |
Clinical Trials Division, Response Oncology Inc, Memphis, TN, USA.
|
| pubmed:publicationType |
Journal Article
|